BioHug Technologies
Assistive Devices for Sensory Processing Disorders
Company Overview
Snapshot
Founded in January 2007 by Raphael (Raffi) Rembrand, BioHug Technologies operates with 1–10 employees. The company focuses on developing assistive and diagnostic devices for sensory-related disorders. In April 2022, BioHug Technologies ceased to operate.
Business overview
BioHug Technologies specializes in researching sensory-related disorders and developing assistive and diagnostic devices for individuals with these conditions, as well as their caregivers and treatment providers. The company's core product, the BioHug Vest, utilizes a patented algorithm to deliver continuous deep pressure, aiming to reduce stress and anxiety levels in individuals with sensory-processing disorders such as autism, ADHD, and PTSD. BioHug Technologies operates within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices and Medical Treatment & Therapeutics categories, serving patients and providers in markets like Israel and Europe.
Strategic signal
In April 2022, BioHug Technologies ceased its operations. This indicates a significant strategic shift, signaling to investors and innovation teams that the company is no longer actively pursuing its mission in the assistive device market for sensory processing disorders.
Log in to access full profile ›Company Intelligence Q&A
- When was BioHug Technologies founded?
- BioHug Technologies was founded in January 2007.
- Who founded BioHug Technologies?
- Raphael (Raffi) Rembrand founded BioHug Technologies.
- What is the primary product of BioHug Technologies?
- The primary product of BioHug Technologies is the BioHug Vest, designed to lower individual stress and anxiety levels using deep pressure for people with sensory-processing disorders.
- What is the operational status of BioHug Technologies?
- BioHug Technologies ceased to operate in April 2022.
- What markets does BioHug Technologies target?
- BioHug Technologies targets geomarkets including Israel and Europe.